Lung Cancer
Volume 69, Issue 2 , Pages 213-217 , August 2010

Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502

  • Takashi Seto

      Affiliations

    • Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 92 541 3231; fax: +81 92 551 4585.
    • ,
  • Takeharu Yamanaka

      Affiliations

    • Cancer Biostatistics Laboratory, National Kyushu Cancer Center, Fukuoka, Japan
    • ,
  • Izumi Wasada

      Affiliations

    • Division of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan
    • ,
  • Nobuhiko Seki

      Affiliations

    • Department of Medical Oncology, Teikyo University School of Medicine, Tokyo, Japan
    • ,
  • Hiroaki Okamoto

      Affiliations

    • Department of Respirology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan
    • ,
  • Takashi Ogura

      Affiliations

    • Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan
    • ,
  • Masahiko Shibuya

      Affiliations

    • Department of Respiratory Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
    • ,
  • Yuichi Takiguchi

      Affiliations

    • Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
    • ,
  • Tetsu Shinkai

      Affiliations

    • Department of Medicine and Thoracic Oncology, Shikoku Cancer Center, Matsuyama, Japan
    • ,
  • Noriyuki Masuda

      Affiliations

    • Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan
    • ,
  • Yukito Ichinose

      Affiliations

    • Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan
    • ,
  • Kenji Eguchi

      Affiliations

    • Department of Medical Oncology, Teikyo University School of Medicine, Tokyo, Japan
    • ,
  • Koshiro Watanabe

      Affiliations

    • Department of Respirology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan

Received 12 July 2009 ,Revised 26 October 2009 ,Accepted 28 October 2009.

References 

  1. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest. 2005;128:947–957
  2. The Elderly Lung Cancer Vinorelbine Italian Study Group . Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66–72
  3. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–372
  4. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–3663
  5. Yamada Y, Toko T, Miyauchi S, Unemi N. Effect of UFT on immune responses in mice. Jpn J Cancer Chemother. 1980;7:2134–2140
  6. Schulz L, Schalhorn A, Wilmanns W, Heinemann V. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells. Proc Am Soc Clin Oncol. 1998;17:251a;(abstr #965)
  7. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 1999;80:1595–1598
  8. Madajewicz S, Hentschel P, Burns P, Caruso R, Fiore J, Fried M, et al. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J Clin Oncol. 2000;18:3553–3557
  9. Ichinose Y, Seto T, Semba H, Itoh K, Inoue Y, Tanaka F, et al. UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer. 2005;93:770–773
  10. Seto T, Yoh K, Asoh H, Yamamoto H, Semba H, Ichinose Y. A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer. Br J Cancer. 2002;86:1701–1704
  11. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004;15:85–106
  12. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 2001;85:939–943
  13. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29–41
  14. Lilenbaum RC, Herndon JE, List MA, Desch C, Watson DM, Miller AA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23:190–196
  15. Sederholm C, Hillerdal G, Lamberg K, Kolbeck K, Dufmats M, Westberg R, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23:8380–8388
  16. Pressacco J, Mitrovski B, Erlichman C, Hedley DW. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res. 1995;55:1505–1508
  17. Pressacco J, Wiley JS, Jamieson GP, Erlichman C, Hedley DW. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer. 1995;72:939–942
  18. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998;58:4349–4357
  19. Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, et al. Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer. 2003;39:1547–1551
  20. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000;60:6075–6079

PII: S0169-5002(09)00571-6

doi: 10.1016/j.lungcan.2009.10.017

Lung Cancer
Volume 69, Issue 2 , Pages 213-217 , August 2010

Article Tools

* Image Usage & Resolution